Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NeuroSigma logo — The future of neurological disorder treatment.

NeuroSigma

The future of neurological disorder treatment.

Founded 2008 United States Los Angeles, United States 16 employees Corporate Round Total: $18.36M Biotechnology

General Information

Company Name NeuroSigma
Founded Year 2008
Location United States Los Angeles, United States
Employees 16
Industries Biotechnology
Funding Stage Corporate Round
Social

BounceWatch is an independent company data service, not affiliated with NeuroSigma. To contact NeuroSigma, visit neurosigma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NeuroSigma compare?

A PDF of NeuroSigma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NeuroSigma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NeuroSigma

NeuroSigma, Inc. is a Los Angeles-based bioelectronics company, pioneering in the field of neurological disorder treatment. The company’s flagship product, the Monarch eTNS® System, utilizes external trigeminal nerve stimulation to address neurological and neuropsychiatric disorders. Notably, in 2019, the FDA cleared this revolutionary medical device for the treatment of pediatric ADHD, marking a significant milestone. Furthermore, the introduction of the Monarch Pediatric Care Co-Pay Program aims to enhance accessibility to eTNS therapy for a larger cohort of children diagnosed with ADHD. NeuroSigma has recently secured a $5.00M Corporate Round investment from KT Corp as of 08 December 2021, further bolstering its position in the Biotechnology industry. This strategic move underscores investor confidence in NeuroSigma's innovative approach to addressing critical neurological disorders and solidifies its foothold in the United States, signifying promising growth prospects.

Business keywords: Neuroscience, Bioelectronics, Neurological Disorders, eTNS Technology, Pediatric Care, FDA Approval, ADHD Treatment, Epilepsy, Depression, Preclinical Research, Clinical Trials, Neuropsychiatric Disorders, Innovation

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Corporate Round $5.00M 1
KT Corp
08 Dec 2021
Convertible Note $11.65M -
31 Aug 2016
Debt Financing $1.21M -
10 Mar 2011
Venture Round $500.00K -
15 Feb 2011

NeuroSigma Alternatives & Competitors

View All Alternatives
NeuroSigma vs
Psy Therapeutics
Psy Therapeutics United States

Creating new futures in central nervous system (CNS) treatment and care.

Seed
11 employees
Biotechnology, Health Care
NeuroSigma vs
Chase Pharmaceuticals
Chase Pharmaceuticals

Pioneering advancements in neuropsychiatric treatment for a brighter future

Series B
11-50 employees
Biotechnology, Health Care
NeuroSigma vs
Quince Therapeutics
Quince Therapeutics United States

Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases

Post-IPO Equity
25 employees
Biotechnology, Health Care
View all alternatives

FAQ About NeuroSigma

The future of neurological disorder treatment.
NeuroSigma was founded in 2008.
NeuroSigma is headquartered in Los Angeles, United States.
NeuroSigma operates in Biotechnology. Its work centres on Neuroscience, Bioelectronics, Neurological Disorders and eTNS Technology.
NeuroSigma has approximately 16 employees.
NeuroSigma has completed 4 funding rounds, raising a total of $18.36M. The latest funding stage is Corporate Round.
Top alternatives and competitors to NeuroSigma include Psy Therapeutics, Chase Pharmaceuticals, Quince Therapeutics, BioAxone Therapeutic, Inc., Addex Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NeuroSigma and Psy Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NeuroSigma, https://bouncewatch.com/company/neurosigma, updated 4 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout